Azelastine Allergen Chamber - Onset of Action Study

Summary

This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day treatment at home.

Timeline

Start

2023-10-30

Primary completion

2024-02-23

Completion

2024-03-18

Drugs

Indications